Clinical trial NCT00478829: Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in China
Official title: Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in 5 Large Cities in China
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adult
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-05-25
Enrollment: 8000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: Objectives: Primary: To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.

Secondary:

* To estimate gender- and age-specific prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.
* To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings such as departments of neurology, gastroenterology, cardiology, and gynecology.
* To describe the recognition and treatment rate by treating physicians as depression and/or anxiety for outpatients in the general health care settings in China.

Detailed description: This study is designed to investigate the status of identifying depression and/or anxiety disorder with somatic symptoms in general hospitals in China. The study will generate valuable information to the medical community; therefore the early and vigorous treatment is possible. It's in line with China government authorities' target to increase the recognition rate of depression and/or anxiety in primary care settings to more than 50% by the end of 2010. The study will also help to identify specific diagnosis and treatment patterns for depressive / anxious patients and their comorbid conditions.

Eligibility criteria: Main Inclusion Criteria:

* Greater than or equal to 18 years.
* Consecutive general internal medical outpatients attending the selected general hospitals in the investigate days(Department of neurology, gastrointestinal, cardiology and gynecology).
* Informed consent obtained for all patients who will undergo a standardized diagnostic assessment by specialized psychiatrists.

Main Exclusion Criteria:

* Patients who have been screened on a previous visit.
* Patients who are unable to complete the survey because of mental or physical incapacity.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
state: Beijing
city: Beijing
country: China
state: Beijing
city: Beijing
country: China
state: Beijing
city: Guangzhou
country: China
state: Guangdong
city: Guangzhou
country: China
state: Guangdong
city: Guangzhou
country: China
state: Guangdong
city: Changsha
country: China
state: Hunan
city: Changsha
country: China
state: Hunan
city: Changsha
country: China
state: Hunan
city: Shanghai
country: China
state: Shanghai
city: Shanghai
country: China
state: Shanghai
city: Shanghai
country: China
state: Shanghai
city: Chengdu
country: China
state: Sichuan
city: Chengdu
country: China
state: Sichuan
city: Chengdu
country: China
state: Sichuan
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
affiliation: For China, medinfo@wyeth.com
name: Trial Manager
role: PRINCIPAL_INVESTIGATOR
References: